More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Positive Data for RECCE 327 in MRSA Burns Wound Infection

Nov 26, 2019 at 11:16 PM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Nov 26, 2019 at 11:16 PM EST

On 6ix: 6ix.com/news/positive-data-for-recce-327-in-mrsa-burns-wound-infection

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • Data Submission & Further Communication Request with US FDAFeb 15, 2018
  • Recce Confirms Pre-IND Data Submission to US FDASep 7, 2017
  • Data from large animal study shows RECCE 327 well toleratedMar 27, 2017

Earlier from Recce Pharmaceuticals

  • Recce Completes Raising of $6.76 millionOct 9, 2019
  • Key Family 2 Patent Granted in Japan for RECCE AntibioticsSep 20, 2019
  • Funding UpdateSep 11, 2019
  • Appendix 4E - Preliminary Final ReportAug 30, 2019
  • FDA Positive Response for Recce Scaled Manufacture & QualityAug 26, 2019

Later from Recce Pharmaceuticals

  • Appendix 4C and CommentaryJan 31, 2020
  • Positive Data from RECCE 327 Antibiotic Safety StudiesFeb 9, 2020
  • Positive Efficacy Data in Kidney/UTI infections animal modelFeb 13, 2020
  • Half Yearly Report and AccountsFeb 27, 2020
  • First-in-Human Clinical Trial Progress UpdateMar 16, 2020
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer